A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant
| Autor: | Sawicki, Gregory S., Chilvers, Mark, McNamara, John, Naehrlich, Lutz, Saunders, Clare, Sermet-Gaudelus, Isabelle, Wainwright, Claire E., Ahluwalia, Neil, Campbell, Daniel, Harris, R. Scott, Paz-Diaz, Hildegarde, Shih, Judy L., Davies, Jane C. |
|---|---|
| Zdroj: | In Journal of Cystic Fibrosis July 2022 21(4):675-683 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect